Any news on Iova stock?

Here is the relevant news and analysis:1. Iovance Biotherapeutics Inc (IOVA) Pre-Market Momentum: Iovance Biotherapeutics Inc (IOVA) experienced a 7.09% pre-market increase. It has an overall score of 77, indicating better value than 77% of stocks. The short-term technical score is 60, suggesting a neutral trading pattern in the past month.2. Positive Sentiment for IOVA: Iovance Biotherapeutics Inc (IOVA) received a bullish score from the InvestorsObserver Stock Sentiment Indicator. This reflects positive investor sentiment in the short term.3. Strong Performance in Premarket Trading: IOVA showed a significant increase of 22.19% in premarket trading. It has an overall score of 83, indicating better value than 83% of stocks. The short-term technical score is 60, suggesting a neutral trading pattern in the past month.4. FDA Approval for Melanoma Drug Amtagvi: Iovance Biotherapeutics Inc (IOVA) saw a 32.7% surge in after-hours trading following FDA approval for its T cell immunotherapy, Amtagvi. This is the first one-time T cell therapy approved by the FDA for solid tumor cancer. The company is also evaluating Amtagvi in a phase III study.Analysis: Iovance Biotherapeutics Inc (IOVA) is showing strong momentum in premarket trading and has received positive sentiment scores. The recent FDA approval of Amtagvi, a T cell immunotherapy for advanced melanoma, is a significant milestone and a potential catalyst for future growth. Investors should consider IOVA's strong overall scores, positive sentiment, and the promising outlook for Amtagvi in their investment decisions.